PCSK9 Patent Fight: Amgen Opposes Doctor Efforts To Keep Praluent On Market

Praulent prescribers try to bolster Sanofi and Regeneron’s argument of the public need for the product but Amgen says their testimony is improper; stay of permanent injunction expires Feb. 21 unless Federal Circuit extends it through appeal.